At #ESMO2026 we’re presenting treatment persistence & clinical characteristics of patients with HR+, HER2- high-risk early breast cancer (EBC) treated with abemaciclib: from a multi-country real-world study. ePoster 615eP Program: https://t.co/lJvrvDTCFD #EBC https://t.co/5teZyuYyef